Clinical trial
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell…
NCT02227251 · Karyopharm Therapeutics Inc, Industry · Recruiting
Key facts
| NCT number | NCT02227251 |
|---|---|
| Title | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
| Official title | A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
| Lead sponsor | Karyopharm Therapeutics Inc, Industry |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diffuse Large B-cell Lymphoma |
| Intervention type | Drug |
| Interventions | Selinexor |
| Enrollment | 244 |
| Start date | Nov 1, 2014 |
| Primary completion | Apr 1, 2027 |
| Completion | Nov 1, 2027 |
| First posted | Aug 28, 2014 |
| Last update posted | Oct 1, 2025 |
| Countries | Australia, Austria, Belgium, Bulgaria, Canada, France, Germany, Greece, Hungary, India, Israel, Italy and 7 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: